-
04:17:01 AM

DCPH Stock News

01/31/23 7:00 AM
Nasdaq : DCPH
earnings
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023. In connection with the earnings release, Deciphera’...
RHEA-AI
neutral
01/24/23 4:02 PM
Nasdaq : DCPH
offering
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters'; Option to Purchase Additional Shares
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,986,111 shares of its common stock. The securities described above were offered by Deciphera...
RHEA-AI
neutral
01/24/23 4:01 PM
Nasdaq : DCPH
clinical trial
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of additional data from the planned exploratory analysis from the INTRIGUE Phase 3 clinical study of QINLOCK ® using circulating...
RHEA-AI
positive
01/03/23 4:02 PM
Nasdaq : DCPH
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today highlighted its strategic outlook for 2023 and planned 2023 corporate milestones, and announced preliminary unaudited fourth quarter and full year 2022 revenue.
RHEA-AI
very positive
01/03/23 4:01 PM
Nasdaq : DCPH
clinical trial
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced findings of a planned exploratory analysis of data from the INTRIGUE Phase 3 clinical study of QINLOCK using circulating tumor DNA from a subgroup of...
RHEA-AI
neutral
01/03/23 7:00 AM
Nasdaq : DCPH
conferences
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
Deciphera Pharmaceuticals, Inc. today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 9:45 AM PT. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.
RHEA-AI
neutral
12/01/22 7:00 AM
Nasdaq : DCPH
conferences
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
Deciphera Pharmaceuticals, Inc. today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 6, 2022 at 10:40 AM ET. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United...
RHEA-AI
neutral